Prognostic value of serological markers of hepatitis B virus infection in squamous cell cervical cancer

Wu, Xingrao; Li, Lan; Li, Yanqing; Jiang, Meiping; Li, Kangming; Li, Zheng; Zhang, Lan

doi:10.7150/jca.61249



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(22):6620-6628. doi:10.7150/jca.61249 This issue Cite

Research Paper

Prognostic value of serological markers of hepatitis B virus infection in squamous cell cervical cancer

Xingrao Wu^1*, Lan Li^1*, Yanqing Li^1*, Meiping Jiang¹, Kangming Li¹, Zheng Li², Lan Zhang^1✉

1. Department of Radiation Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, No. 519, Kunzhou Road, Kunming 650118, People's Republic of China.
2. Department of Gynecologic Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, No. 519, Kunzhou Road, Kunming 650118, People's Republic of China.
*These authors contributed equally to this article.

Citation:

Wu X, Li L, Li Y, Jiang M, Li K, Li Z, Zhang L. Prognostic value of serological markers of hepatitis B virus infection in squamous cell cervical cancer. J Cancer 2021; 12(22):6620-6628. doi:10.7150/jca.61249. https://www.jcancer.org/v12p6620.htm

Other styles

Abstract

Objective: The current study aimed to investigate the prognostic value of serological markers of hepatitis B virus (HBV) infection in squamous cell cervical cancer.

Methods: Squamous cell cervical cancer patients treated by concurrent chemoradiotherapy from January 2013 to December 2015 at Yunnan Cancer Hospital were retrospectively reviewed.

Results: Of a total of 277 patients, 12 (4.33%), 93 (33.57%), 2 (0.72%), 25 (9.02%), and 36 patients (13.00%) were seropositive for hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antibodies (anti-HBs), hepatitis B envelope antigen (HBeAg), anti-hepatitis B envelope antibodies (anti-HBe), and anti-hepatitis B core antibodies (anti-HBc), respectively. No patients experienced more than mild hepatic adverse events during treatment. The five-year overall survival (OS) rates for patients with anti-HBs positive or negative status were 85.8% and 66.2% (p = 0.039), respectively. No statistically significant difference in the five-year OS rates was observed in HBsAg positive and negative, HBeAg positive and negative, anti-HBe positive and negative, anti-HBc positive and negative patients. The multivariable analysis revealed that anti-HBs positivity was an independent favorable prognostic factor for OS (HR= 0.279; 95%CI: 0.083-0.936; p = 0.039) in patients younger than 50 years.

Conclusions: The presence of anti-HBs predicts a superior OS for squamous cell cervical cancer patients aged younger than 50 years.

Keywords: cervical cancer, hepatitis B virus, serologic markers, prognosis

Citation styles

APA

Wu, X., Li, L., Li, Y., Jiang, M., Li, K., Li, Z., Zhang, L. (2021). Prognostic value of serological markers of hepatitis B virus infection in squamous cell cervical cancer. Journal of Cancer, 12(22), 6620-6628. https://doi.org/10.7150/jca.61249.

ACS

Wu, X.; Li, L.; Li, Y.; Jiang, M.; Li, K.; Li, Z.; Zhang, L. Prognostic value of serological markers of hepatitis B virus infection in squamous cell cervical cancer. J. Cancer 2021, 12 (22), 6620-6628. DOI: 10.7150/jca.61249.

NLM

CSE

Wu X, Li L, Li Y, Jiang M, Li K, Li Z, Zhang L. 2021. Prognostic value of serological markers of hepatitis B virus infection in squamous cell cervical cancer. J Cancer. 12(22):6620-6628.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.